TY  - JOUR
T1  - Melissa officinalis Extract Reduces the Antiproliferative Efficacy of Osimertinib in NSCLC Cells by Inhibiting Apoptotic Signaling
TT  - Melissa officinalis Ekstraktı Apoptotik Sinyallemeyi Engelleyerek Osimertinibin KHDAK Hücrelerindeki Antiproliferatif Etkinliğini Azaltmaktadır
AU  - Sezgin, Esra Tuba
AU  - Çankaya, Murat
PY  - 2025
DA  - October
Y2  - 2025
DO  - 10.7161/omuanajas.1664445
JF  - Anadolu Tarım Bilimleri Dergisi
JO  - ANAJAS
PB  - Ondokuz Mayıs University
WT  - DergiPark
SN  - 1308-8750
SP  - 447
EP  - 464
VL  - 40
IS  - 3
LA  - en
AB  - Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. The most significant problem in treatment is the resistance that develops over time against osimertinib (OSI), an irreversible, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits EGFR T790M resistance mutations, which are among the activating mutations of the EGFR. Many studies have shown that certain phytochemicals can overcome drug resistance in cancer cells. Additionally, the fact that they have fewer side effects compared to drugs has made plants popular in cancer treatment. Melissa officinalis (M. officinalis) is a plant with antiproliferative properties widely used in the treatment of various cancer types, having shown significant results in many human cancer cell lines. In this study, the antagonistic anticancer effect of M. officinalis plant extract and osimertinib was investigated on the PC-9 NSCLC cell line. According to the calculation of the results obtained by the MTT method using CompuSyn software, the combination of 50 nM osimertinib and 50 µg ml-1 M. officinalis methanol extract showed the best antagonistic effect (CI: 3031.44) after 48h of incubation in PC-9 cells. The gene expression levels and protein levels of BCL-2 associated X protein (BAX), B-cell lymphoma 2 (BCL-2) and Caspase 3 (CASP3) were determined at this concentration combination by RT-qPCR and ELISA methods, respectively. And the results showed that this combination inactivates the intrinsic apoptotic pathway in the PC-9 cell line.
KW  - Lung cancer
KW  - Chemoresistance
KW  - Melissa officinalis
KW  - Osimertinib
N2  - Dünyada kansere bağlı ölümlerin başında küçük hücreli dışı akciğer kanseri (KHDAK) gelmektedir. Tedavide görülen en önemli problem; epidermal büyüme faktörü reseptörü (EGFR) aktive edici mutasyonlardan olan EGFR T790M direnç mutasyonlarını seçici olarak inhibe eden geri dönüşsüz ve üçüncü nesil bir EGFR-tirozin kinaz inhibitörü (TKİ) olan osimertinibe karşı zamanla gelişen dirençtir. Bazı fitokimyasalların kanser hücrelerinin ilaç direncini aşabileceğine dair birçok çalışma bulunmaktadır. Yine ilaçlara göre daha az yan etkiye sahip olmaları da bitkileri kanser tedavisinde popüler hale getirmiştir. Melissa officinalis (M. officinalis) de çeşitli kanser türlerinin tedavisinde yaygın olarak kullanılmakta olan antiproliferatif özellikleri nedeniyle pek çok insan kanser hücre hattında çalışılmış ve anlamlı sonuçlar elde edilmiştir. Bu çalışmada PC-9 KHDAK hücre hattı üzerinde M. offıcinalis bitki ekstraktı ve osimertinibin sinerjik antikanser etkisi incelenmiştir. CompuSyn yazılımı kullanılarak MTT yöntemi ile alınan sonuçların hesaplanmasına göre 50 nM osimertinib ve 50 µg ml-1 M. officinalis metanol ekstresi kombinasyonu PC-9 hücrelerinde 48 saatlik inkübasyon sonunda en iyi antagonisitk etkiyi (CI: 3031.44) göstermiştir. Bu konsantrasyon kombinasyonunda BCL-2 ilişkili X proteini (BAX), B-hücreli lenfoma 2 (BCL-2) ve Kaspaz 3 (CASP3) gen ifade seviyeleri ve protein düzeyleri sırasıyla RT-qPCR ve ELISA yöntemi ile belirlenmiştir. Ve sonuçlar gösterdi ki, bu kombinasyon PC-9 hücre hattında intrinsik apoptotik yolağı inaktive etmiştir.
CR  - Global Cancer Observatory (2022, Şubat 18). https://gco.iarc.fr/today/en/dataviz/tables?mode=cancer&types=1&group_populations=0&multiple_populations=1&populations=900
CR  - Abughanimeh, O., Kaur, A., El Osta, B., Ganti, A. K. 2022. Novel targeted therapies for advanced non-small lung cancer. In Seminars in Oncology (Vol. 49, No. 3-4, pp. 326-336). WB Saunders. https://doi.org/10.1053/j.seminoncol.2022.03.003
CR  - Bilgin, B., Yücel, Ş. 2019. Clinical Feature and Survival Outcomes of Lung Cancer with ALK Mutation Positive and Treated with Crizotinib, Single Centre Experience. Acta Oncologica Turcica, 52 (2), 208-212.doi: 10.5505/aot.2019.52523
CR  - Bircan, S., Çandır, Ö., Kapucuoğlu, N., Başpınar, Ş. 2005. Bazal hücreli karsinom ve çevre nontümöral epidermiste p53, bcl-2, bax ekspresyonu. Turkish Pathology, 21(3-4), 44-8.doi: 10.5146/tjpath.2012.01110
CR  - Chang, A. 2011. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung cancer, 71(1), 3-10.doi: 10.1016/j.lungcan.2010.08.022
CR  - Chen, Z., Vallega, K. A., Chen, H., Zhou, J., Ramalingam, S. S., Sun, S. Y. 2022. The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition. Pharmacological research, 175, 105998.doi: 10.1016/j.phrs.2021.105998
CR  - Darji, P., Patel, J., Patel, B., Chudasama, A., Ivan, P., Fnu, J., Nalla, S. 2024. A Comprehensive Review On Anticancer Natural Drug, World Journal of Pharmacy and Pharmaceutical Sciences, 13, 717-734.doi:10.20959/wjpps20244-27049
CR  - Dirican, A., Dirican, N., Ölmezoğlu, A. 2016. İleri Evre Küçük Hücreli Dışı Akciğer Kanserinde Hedef Driver Mutasyonların Tespitinde Likit Biyopsi Doku Biyopsisinin Yerini Alabilir mi? Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi, 3(2), 165-168.
CR  - Ebrahimnezhad Darzi, S., Amirghofran, Z. 2013. Dichloromethane fraction of Melissa officinalis induces apoptosis by activation of intrinsic and extrinsic pathways in human leukemia cell lines. Immunopharmacol Immunotoxicol, 35(3), 313-320. doi: 10.3109/08923973.2013.768268
CR  - Faraji, P., Araj-Khodaei, M., Ghaffari, M., Dolatabadi, J. E. N. 2021. Anticancer effects of Melissa officinalis: a traditional medicine. Pharmaceutical Sciences, 28(3), 355-364.doi:10.34172/PS.2021.43
CR  - Herbst, R. S., Morgensztern, D., Boshoff, C. 2018. The biology and management of non-small cell lung cancer. Nature, 553(7689), 446-454.doi: 10.1038/nature25183
CR  - Huang, G., Liu, X., Jiang, T., Cao, Y., Sang, M., Song, X., Zheng, X. 2023. Luteolin overcomes acquired resistance to osimertinib in non-small cell lung cancer cells by targeting the HGF-MET-Akt pathway. American Journal of Cancer Research, 13(9), 4145.
CR  - Huang, W., Chen, J. J., Xing, R., Zeng, Y. C. 2021. Combination therapy: future directions of immunotherapy in small cell lung cancer. Translational Oncology, 14(1), 100889. https://doi.org/10.1016/j.tranon.2020.100889
CR  - Jahanban-Esfahlan, R., Seidi, K., Monfaredan, A., Shafie-Irannejad, V., Abbasi, M. M., Karimian, A., Yousefi, B. 2017. The herbal medicine Melissa officinalis extract effects on gene expression of p53, Bcl-2, Her2, VEGF-A and hTERT in human lung, breast and prostate cancer cell lines. Gene, 613, 14-19.doi: 10.1016/j.gene.2017.02.034
CR  - Konishi, H., Haga, Y., Lin, Y., Tsujino, H., Higashisaka, K., Tsutsumi, Y. 2023. Osimertinib-tolerant lung cancer cells are susceptible to ferroptosis. Biochemical and Biophysical Research Communications, 641, 116-122. https://doi.org/10.1016/j.bbrc.2022.12.029
CR  - Li, J., Kwok, H. F. 2020. Current strategies for treating NSCLC: from biological mechanisms to clinical treatment. Cancers, 12(6), 1587. https://doi.org/10.3390/cancers12061587
CR  - Li, Y., Mao, T., Wang, J., Zheng, H., Hu, Z., Cao, P., Lin, F. 2023. Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer. Cell Communication and Signaling, 21(1), 71.https://doi.org/10.1186/s12964-023-01082-8
CR  - Lu, H. F., Chie, Y. J., Yang, M. S., Lee, C. S., Fu, J. J., Yang, J. S., Chung, J. G. 2010. Apigenin induces caspase-dependent apoptosis in human lung cancer A549 cells through Bax-and Bcl-2-triggered mitochondrial pathway. International journal of oncology, 36(6), 1477-1484.doi: 10.3892/ijo_00000634
CR  - Majolo, F., Delwing, L. K. D. O. B., Marmitt, D. J., Bustamante-Filho, I. C., Goettert, M. I. 2019. Medicinal plants and bioactive natural compounds for cancer treatment: Important advances for drug discovery. Phytochemistry Letters, 31, 196-207.doi:10.1016/j.phytol.2019.04.003
CR  - Miraj, S., Rafieian-Kopaei, & Kiani, S. 2017. Melissa officinalis L: A Review study with an antioxidant prospective. Journal of evidence-based complementary & alternative medicine, 22(3),385-394.doi:10.1177/2156587216663433
CR  - Ni, Y., Liu, J., Zeng, L., Yang, Y., Liu, L., Yao, M., Li, W. 2023. Natural product manoalide promotes EGFR-TKI sensitivity of lung cancer cells by KRAS-ERK pathway and mitochondrial Ca2+ overload-induced ferroptosis. Frontiers in Pharmacology, 13, 1109822.doi: 10.3389/fphar.2022.1109822
CR  - Präbst, K., Engelhardt, H., Ringgeler, S., & Hübner, H. 2017. Basic colorimetric proliferation assays: MTT, WST, and resazurin. Cell viability assays: methods and protocols, 1-17.doi: 10.1007/978-1-4939-6960-9_1
CR  - Rasgele, P. G., Yoldas, P. A., Sipahi, N., Ucan, H. 2024. Investigation and Characterization of Novel Biologically Active Secondary Metabolites from Melissa officinalis L. Pharmaceutical Chemistry Journal, 57(11), 1789-1798.doi:10.1007/s11094-024-03080-7
CR  - Schmid, S., Li, J. J., Leighl, N. B. 2020. Mechanisms of osimertinib resistance and emerging treatment options. Lung Cancer, 147, 123-129.doi: 10.1016/j.lungcan.2020.07.014
CR  - Schoenfeld, A. J., Helena, A. Y. 2020. The evolving landscape of resistance to osimertinib. Journal of Thoracic Oncology, 15(1), 18-21.doi: 10.1016/j.jtho.2019.11.005
CR  - Shakeri, A., Sahebkar, A., Javadi, B. 2016. Melissa officinalis L.–A review of its traditional uses, phytochemistry and pharmacology. Journal of ethnopharmacology, 188, 204-228.doi: 10.1016/j.jep.2016.05.010
CR  - Tang, Z. H., Lu, J. J. 2018. Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer letters, 420, 242-246.doi: 10.1016/j.canlet.2018.02.004
CR  - Vallega, K. A., Sun, S. Y. 2020. Does the natural product, honokiol, have value in the battle against osimertinib resistance?. Oncoscience, 7(9-10), 73. doi: 10.18632/oncoscience.517
CR  - Velinovic, M., Jankovic, R., Jovanovic, D., Skodric Trifunovic, V., Gavrilovic, D., Stojsic, J., Cavic, M. 2019. Tumor characteristics, expressions of ERCC1, Bax, p53, IGF1R, Bcl2, Bcl2/Bax and prognostic factors for overall survival in patients with lung carcinoid. J buon, 24(1), 256-266.
CR  - Wang, P., Yang, H. L., Yang, Y. J., Wang, L., Lee, S. C. 2015. Overcome cancer cell drug resistance using natural products. Evidence‐based Complementary and Alternative Medicine, 2015(1), 767136. doi: 10.1155/2015/767136
CR  - Wangari-Talbot, J., Hopper-Borge, E. 2013. Drug resistance mechanisms in non-small cell lung carcinoma. Journal of cancer research updates, 2(4), 265.doi: 10.6000/1929-2279.2013.02.04.5
CR  - Wesarg, E., Hoffarth, S., Wiewrodt, R., Kröll, M., Biesterfeld, S., Huber, C., Schuler, M. 2007. Targeting BCL‐2 family proteins to overcome drug resistance in non‐small cell lung cancer. International Journal of Cancer, 121(11), 2387-2394. doi: 10.1002/ijc.22977
CR  - Yardley, D. A. 2013. Drug resistance and the role of combination chemotherapy in improving patient outcomes. International journal of breast cancer, 2013(1), 137414.doi: 10.1155/2013/137414
CR  - Zang, H., Qian, G., Arbiser, J., Owonikoko, T. K., Ramalingam, S. S., Fan, S., Sun, S. Y. 2020. Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol. Molecular Oncology, 14(4), 882-895. doi: 10.1002/1878-0261.12645
UR  - https://doi.org/10.7161/omuanajas.1664445
L1  - https://dergipark.org.tr/en/download/article-file/4720348
ER  -